Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0400 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.395 |
| Open | 1.36 |
| 1-Year Change | -58.37% |
| Day's Range | 1.275 - 1.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.3950 | 0.0750 | 5.68% | 1.3200 | 1.4050 | 1.3200 |
| Apr 23, 2025 | 1.3150 | 0.0350 | 2.73% | 1.2800 | 1.3600 | 1.2800 |
| Apr 22, 2025 | 1.3050 | 0.0150 | 1.16% | 1.2900 | 1.3400 | 1.2700 |
| Apr 21, 2025 | 1.2950 | -0.0250 | -1.89% | 1.3200 | 1.3450 | 1.2550 |
| Apr 17, 2025 | 1.3650 | 0.0150 | 1.11% | 1.3500 | 1.4100 | 1.3150 |
| Apr 16, 2025 | 1.3600 | 0.0600 | 4.62% | 1.3000 | 1.3600 | 1.3000 |
| Apr 15, 2025 | 1.3250 | 0.0250 | 1.92% | 1.3000 | 1.3500 | 1.2850 |
| Apr 14, 2025 | 1.3250 | -0.0350 | -2.57% | 1.3600 | 1.3750 | 1.2700 |
| Apr 11, 2025 | 1.3350 | 0.0750 | 5.95% | 1.2600 | 1.3800 | 1.2400 |
| Apr 10, 2025 | 1.2750 | -0.0600 | -4.49% | 1.3350 | 1.3700 | 1.2600 |
| Apr 9, 2025 | 1.3300 | 0.0700 | 5.56% | 1.2600 | 1.3950 | 1.2100 |
| Apr 8, 2025 | 1.2550 | -0.0850 | -6.34% | 1.3400 | 1.3400 | 1.2500 |
| Apr 7, 2025 | 1.3050 | 0.0700 | 5.67% | 1.2350 | 1.4550 | 1.2350 |
| Apr 4, 2025 | 1.2950 | 0.1550 | 13.60% | 1.1400 | 1.3050 | 1.1300 |
| Apr 3, 2025 | 1.2650 | 0.0450 | 3.69% | 1.2200 | 1.3400 | 1.2150 |
| Apr 2, 2025 | 1.2950 | 0.0750 | 6.15% | 1.2200 | 1.3250 | 1.2200 |
| Apr 1, 2025 | 1.2350 | 0.0250 | 2.07% | 1.2100 | 1.2800 | 1.1900 |
| Mar 31, 2025 | 1.2050 | -0.0350 | -2.82% | 1.2400 | 1.3500 | 1.1600 |
| Mar 28, 2025 | 1.4950 | -0.1950 | -11.54% | 1.6900 | 1.6900 | 1.4950 |
| Mar 27, 2025 | 1.6450 | -0.0050 | -0.30% | 1.6500 | 1.6850 | 1.5500 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com